Ease up, the Delhi High Court said to drug regulators who sent dunning notices to pharmaceutical companies that allegedly did not cooperate with the latest round of price caps that is routinely revised for products under a list of 348 drugs deemed essential.
Strides Shasun has resumed limited production at its Cuddalore API plant in India following a fire last week that killed one worker.
As with most corporate chiefs, Biocon's normally would be pleased with India's proposal to lower the nation's corporate tax rate to 25% from 30%. But, if it means eliminating tax exemptions for investments in research and development, Biocon is opposed.
India's efforts to smooth over trade disputes with the European Union will lead to a resumption of bilateral talks early next year, but GVK Biosciences will have to be satisfied with watching from the sidelines.
India's Zydus Cadila could be about to shake up the India market for diabetes drugs with its Nov. 20 launch of Tenglyn (teneligliptin) for controlling hypoglycemia associated with the Type 2 version of the disease.
A court in New Delhi has given permission for the Drug Controller General of India to process the application by Reliance Life Sciences for a breast cancer drug package.
As the rest of the world focuses on finding treatments for increasingly drug-resistant forms of tuberculosis, India awaits the outcome of a trial on what would be its first new drug for the disease in 40 years, according to news reports.
Suggesting that India's chief drug regulator may not be doing enough to protect certain volunteers in clinical trials, the Supreme Court ordered the agency to provide adequate oversight, particularly when drugs to treat the human papillomavirus are concerned.
The appointment of a new Controller-General for Patents, Designs and Trademarks in India has delayed the compulsory license application by Lee Pharma, which wants to produce the diabetes drug saxagliptin developed and patented by London-based AstraZeneca, according to a report by The Hindu.
GlaxoSmithKline is making a move to beef up its vaccine business in India and has started the ball rolling with a price cut on its pneumonia vaccine Synflorix and set the stage for two product launches in 2016, according to a report by the Business Standard.